Prevalence and characteristics of metabolic dysfunction-associated steatohepatitis among pediatric patients in the MarketScan Databases
MASH is more prevalent among pediatric patients with comorbid conditions such as metabolic syndrome, obesity, and T2D, which appears to be similar to young adults. Rising prevalence of childhood obesity and related comorbid conditions, and the progressive nature of MASH, make this an area of increasing medical need. Prescreening MASH among high-risk patients with these comorbidities is needed for target intervention.
Authors
- Samuel S. Engel (ORCID: https://orcid.org/0000-0002-4439-6356)
- Kennedy M. Peter‐Marske (ORCID: https://orcid.org/0000-0002-7085-7072)
- R. Ravi Shankar (ORCID: https://orcid.org/0000-0002-3709-0965)
- Gail Fernandes (ORCID: https://orcid.org/0000-0002-9654-2634)
- Tongtong Wang (ORCID: https://orcid.org/0000-0001-7621-7781)
- Xinyue Liu (ORCID: https://orcid.org/0009-0002-3299-0806)
- Xiao Zhang (ORCID: https://orcid.org/0000-0002-7584-0712)
Institutions
- University of North Carolina at Chapel Hill (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Amgen (United States) (US)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-10-27
- DOI
- https://doi.org/10.1371/journal.pone.0334971
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- International Business Machines Corporation